top of page

CEBINA Bridge Capital aims to provide absolute return by strategically investing in promising pharmaceutical drug discovery and biotech projects throughout Central and Eastern Europe.

Learn More

What We Do

Welcome to CEBINA Bridge Capital.

Our Mission

We are a specialized fund that invests in pharmaceutical drug development in Central and Eastern Europe.

We provide investors with access to the evolving biotech and pharmaceutical sector in the region, benefiting from the deep scientific and market knowledge of our strategic partners.

What We Do – Our Mission

At CEBINA Bridge Capital, our mission is to accelerate the discovery and development of innovative drugs within the Central and Eastern European (CEE) region.

By fostering collaboration between research institutions, biotech firms, and industry leaders, we aim to create a thriving ecosystem that drives scientific advancement, economic growth, and improved patient outcomes.



Especially in the CEE, in past times the focus of university institutions was on teaching and basic research, whereas facilitation of commercial exploitation of research results tended to take a back seat. Even today, this region offers many treasures in basic research – opportunities waiting to be discovered by experts for development.



It is often difficult to bring breakthroughs from basic academic research to the patient, or “from bench to bed”.

After academic funding, and before classic seed financing of early clinical trials, there is a gap, also called the “valley of death”. In this translation phase, when findings from basic research mature into lead compounds for clinical testing, development projects are particularly vulnerable to not having sufficient funding.


CEBINA Bridge Capital bridges this gap and provides early-stage investment opportunities in carefully selected research projects, aiming for absolute return to participating shareholders.

Our Approach

How We Do It – Our Approach

CEBINA Bridge Capital has entered into a collaboration agreement - DANUBE LABS - for the purpose of identifying and supporting pharmaceutical drug discovery projects originating from universities, research institutes and other entities in Central and Eastern Europe. 

DANUBE LABS is funded by CEBINA Bridge Capital and collaborates with CEBINA and Evotec.

CEBINA is a biotech incubator and accelerator and product development and research company based in Vienna. With a strong network in the CEE region, CEBINA is responsible for identifying and assessing promising drug discovery projects. CEBINA also supervises the investments, protecting and maintaining Intellectual Property rights.

Evotec is a global leader in drug discovery, providing research and drug development services to the pharmaceutical and biotechnology industry, and conducting research and development activities for internal and partnered drug development programs. Evotec provides discovery, research, preclinical, development and other related services to CEBINA in support of identified high-potential projects.

DANUBE LABS, funded by CEBINA Bridge Capital, emerges as a high-profile initiative to foster and commercialize innovations from the CEE region, and to ultimately make them beneficial and accessible to patients.


Investment Director CEBINA Bridge Capital Ltd
Patrick Aisher

Patrick Aisher is a serial entrepreneur who has invested in the life science industry since 1997. He has focused on biomedical technology companies developing medical devices, biopharmaceuticals, and healthcare services in over 40 direct investments. Aisher has a broad portfolio including various successful NASDAQ exits, two exits via trade sale at $40M (KB Medical to Globus in 2018) and $150M+ (Medina Medical to Medtronic in 2016) respectively, and two exits via international licensing transactions valued at $350M+. He is a partner in a $200M venture fund for private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. He is a Director of Aleva Neurotherapeutics SA, PreComb Therapeutics AG, and has identified and invested in early stage spin-off opportunities from Universities in Barcelona, Zurich, Oxford, Boston, Stanford, NorthEastern, Texas, NYU, Lausanne and Geneva

Strategic Advisor & Investor Relations
Stefanie Kearney

Stefanie Kearney has a background in life sciences and digital health with nearly two decades of management experience in the pharmaceutical industry. She has led companies form start-up phase to IPO.

Her understanding of the intricacies involved in growing businesses in complex markets is accompanied by her proficiency in building bridges between companies and stakeholders.

Meet the team

Media Mentions



As an investor and investment advisor, CEBINA Bridge Capital strives to combine good financial performance with its environmental and social objectives, while at the same time observing the principles of good corporate governance.


Since the establishment of the World Commission on Environment and Development by the United Nations, sustainable development has become more and more interpreted and accepted as an overarching concept to ensure the continuity of our planet. Sustainable development is defined as development that meets the needs of the present without compromising the ability of future generations to meet their own needs.

Businesses all over the world are adapting, moving environmental, social and governance (ESG) issues from the periphery of strategic concern to the centre. They’re acknowledging ESG as a driver of value creation and urgently developing a proactive ESG mindset.


1  —



2  —

Social Equality


3 —



As intermediaries between investors and capital-seeking companies and organizations, financial institutions can help to ensure that capital is invested sustainably, both from an environmental and a social perspective.

Gibraltar FSC – AIFMD Fund

The Alternative Investment Fund Managers Directive 2011/61/EU (AIFMD) is a European Directive which was transposed into Gibraltar legislation via the Financial Services (Alternative Investment Fund Managers) Regulations 2013. The European Commission has supplemented the AIFMD with a Delegated Regulation, more commonly known as the level 2 implementing measures (Level 2).

With the implementation of the AIFMD, all EU funds will either be Undertakings for Collective Investment in Transferable Securities (UCITS) or Alternative Investment Funds (AIFs). Therefore, the scope of the AIFMD is very large and covers Experienced Investor Funds (EIFs), authorised funds, private funds and some recognised funds. The AIFMD however does not directly regulate the operations of AIFs but instead regulates the managers of the AIFs; i.e. the alternative investment fund managers (AIFMs).

Small AIFMs” are AIFMs which either directly or indirectly, through a company with which the AIFM is linked by common management or control, or by substantive direct or indirect holding, manage portfolios of AIFs whose assets under management:

(a) including any assets acquired through use of leverage, in total do not exceed a threshold of EUR100 million; or 

(b) in total do not exceed a threshold of EUR500 million when the portfolios of AIFs consist of AIFs that are unleveraged and have no redemption rights exercisable during a period of 5 years following the date of initial investment in each AIF.


The above thresholds are commonly referred to as the “de minimis thresholds”.


Although Small AIFMs do not fall within the full scope of AIFMD they are still required to register with the FSC in accordance with Article 3 of the AIFMD. However, small non-EU AIFMS which manage EU AIFs (this includes Gibraltar AIFs) only have to register with the FSC if they are marketing the EU AIF in Gibraltar until 2015.


Only Articles 3(3), (4) and 46 of the AIFMD apply to Small AIFMS.


For further information, please refer to the Gibraltar FSC information page “AIFMD – Small AIFMs”.

bottom of page